Cipaglucosidase alfa

Cipaglucosidase alfa
Clinical data
Other namesATB-200, ATB200
Routes of
administration		Intravenous
Drug classEnzyme replacement
ATC code
Legal status
Legal status
  • UK: Early access to medicines scheme [1]
Identifiers
CAS Number
DrugBank
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC4489H6817N1197O1298S32
Molar mass99347.92 g·mol−1

Cipaglucosidase alfa is an experimental enzyme replacement therapy medication for the treatment of glycogen storage disease type II (Pompe disease). Cipaglucosidase alfa is a recombinant human acid α-glucosidase enzyme replacement therapy that provides an exogenous source of acid α-glucosidase.[2]

Society and culture

Cipaglucosidase alfa is available in the UK, since June 2021, under the Early Access to Medicines Scheme.[1]

On 15 December 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Pombiliti, intended for the treatment of glycogen storage disease type II (Pompe disease).[2] The applicant for this medicinal product is Amicus Therapeutics Europe Limited.[2]

Names

Cipaglucosidase alfa is the international nonproprietary name (INN).[3]

References

  1. 1 2 "Cipaglucosidase alfa with miglustat: Treatment protocol: Information for healthcare professionals". Medicines and Healthcare products Regulatory Agency (MHRA). 8 June 2021. Retrieved 18 December 2022.
  2. 1 2 3 "Pombiliti: Pending EC decision". European Medicines Agency (EMA). 16 December 2022. Retrieved 18 December 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  3. ↑ World Health Organization (2021). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 85". WHO Drug Information. 35 (1). hdl:10665/340684.

Further reading

  • Schoser B, Roberts M, Byrne BJ, Sitaraman S, Jiang H, Laforêt P, et al. (December 2021). "Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial". The Lancet. Neurology. 20 (12): 1027–1037. doi:10.1016/S1474-4422(21)00331-8. PMID 34800400. S2CID 244304730.


This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.